Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Receives Average Recommendation of “Reduce” from Brokerages

Shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) have been given a consensus rating of “Reduce” by the six analysts that are presently covering the company, MarketBeat reports. Three analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and one has issued a buy recommendation on the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $30.00.

A number of equities analysts have weighed in on FMS shares. Bank of America downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “neutral” rating to an “underperform” rating in a research note on Wednesday, October 15th. UBS Group lowered Fresenius Medical Care AG & Co. KGaA from a “sell” rating to an “underperform” rating in a research report on Wednesday, October 15th. Zacks Research lowered Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 4th. Wall Street Zen upgraded Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “strong-buy” rating in a report on Saturday. Finally, Weiss Ratings raised Fresenius Medical Care AG & Co. KGaA from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, October 8th.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Hennessy Advisors Inc. bought a new stake in shares of Fresenius Medical Care AG & Co. KGaA in the 2nd quarter valued at approximately $11,479,000. Millennium Management LLC lifted its stake in Fresenius Medical Care AG & Co. KGaA by 50.0% during the first quarter. Millennium Management LLC now owns 1,083,602 shares of the company’s stock worth $26,982,000 after purchasing an additional 361,364 shares during the last quarter. Raymond James Financial Inc. boosted its holdings in Fresenius Medical Care AG & Co. KGaA by 1,508.1% in the first quarter. Raymond James Financial Inc. now owns 287,751 shares of the company’s stock worth $7,165,000 after purchasing an additional 269,857 shares during the period. Bank of America Corp DE boosted its holdings in Fresenius Medical Care AG & Co. KGaA by 279.7% in the second quarter. Bank of America Corp DE now owns 337,316 shares of the company’s stock worth $9,637,000 after purchasing an additional 248,477 shares during the period. Finally, Pzena Investment Management LLC increased its stake in Fresenius Medical Care AG & Co. KGaA by 1.0% during the third quarter. Pzena Investment Management LLC now owns 14,816,852 shares of the company’s stock valued at $390,128,000 after purchasing an additional 153,870 shares during the last quarter. 8.37% of the stock is currently owned by institutional investors.

Fresenius Medical Care AG & Co. KGaA Stock Performance

FMS opened at $23.94 on Tuesday. Fresenius Medical Care AG & Co. KGaA has a 12 month low of $22.05 and a 12 month high of $30.46. The business has a 50-day moving average of $24.60 and a two-hundred day moving average of $25.68. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.00 and a current ratio of 1.36.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last announced its quarterly earnings data on Tuesday, November 4th. The company reported $0.64 earnings per share for the quarter, topping the consensus estimate of $0.59 by $0.05. Fresenius Medical Care AG & Co. KGaA had a net margin of 3.72% and a return on equity of 7.42%. The business had revenue of $5.73 billion for the quarter, compared to analyst estimates of $4.72 billion. Sell-side analysts anticipate that Fresenius Medical Care AG & Co. KGaA will post 1.51 EPS for the current fiscal year.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.